This article is more than 5 years old. Information may no longer be current.

Avedro shipping Photrexa Viscous and Photrexa for cross-linking procedures

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Avedro announced the launch and shipment of Photrexa Viscous and Photrexa, two FDA-approved drugs used in corneal collagen cross-linking procedures with the KXL System.

In April, the FDA approved Photrexa Viscous, Photrexa and the KXL System to be used in cross-linking for the treatment of progressive keratoconus. The second indication for the products, for the treatment of corneal ectasia following refractive surgery, received FDA approval in July.

“We are proud to announce that FDA-approved cross-linking treatments are now a reality, and our Photrexa drug products are now available. Clinicians have already started to treat their patients in the U.S. who are suffering from progressive keratoconus or corneal ectasia,” Reza Zadno, PhD, CEO of Avedro, said in a company press release.

This is the only corneal collagen cross-linking therapy approved by the FDA.